Pharmaceutical

Cardurion closes $260m in Series B to develop cardiovascular pipeline

The funds will finance late-stage trials of CRD-750, a PDE9 inhibitor for heart failure, and CRD-4730, a CaMKII inhibitor.

Jul 18, 2024 - 04:00
Cardurion closes $260m in Series B to develop cardiovascular pipeline
The funds will finance late-stage trials of CRD-750, a PDE9 inhibitor for heart failure, and CRD-4730, a CaMKII inhibitor.
Read the original article

Tags:

Previous Article

CatalYm secures $150m to advance GDF-15-targeting immune modulator   

Next Article

The US Biosecure Act threatens to destabilise the pharmaceutical industry 

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Gilead urged to improve access to HIV drug by public figures and celebrities

Gilead urged to improve access to HIV drug by public fi...

May 31, 2024

STAT+: Lawmakers press CMS to release new breakthrough device coverage rule

STAT+: Lawmakers press CMS to release new breakthrough ...

May 11, 2023

Opinion: The best way to convince healthy people to get insurance is not ‘because it’s in your financial interest’

Opinion: The best way to convince healthy people to get...

Nov 3, 2023